Kenox Pharmaceuticals

Kenox Pharmaceuticals, founded in 2016 and headquartered in Princeton, New Jersey, is a specialized CDMO in the aerosol drug delivery space. It leverages over 100 collective years of industry experience to provide end-to-end services for inhalation, nasal, and ophthalmic spray products, combining large-company expertise with small-company agility. The company's expansion into GMP facilities positions it to support clients from development through to first-in-human clinical studies, targeting a niche but critical segment of the pharmaceutical services market.

Aerosol and spray drug delivery platform for inhalation (Nebulizers, SMIs, DPIs, MDIs), intranasal (Unit-/Bi-Dose, Multidose), and ophthalmic (soft mist, drops) applications. Provides end-to-end formulation development, manufacturing, and testing services for drug-device combination products.

Kenox competes with other specialized CDMOs focusing on inhalation and nasal products (e.g., Aptar Pharma's services division, Kindeva Drug Delivery, Battelle) as well as the broader CDMO market. Its differentiation lies in its specific aerosol expertise, combined service offering, and emphasis on small-company agility paired with deep industry experience.